Neuropathogenicity of non-viable Borrelia burgdorferi ex vivo
01.13.2022 |
arrow_forwardLymeX Diagnostics Prize
01.07.2022 |
arrow_forwardLymeX Diagnostics Prize
01.01.2022 |
arrow_forwardCenters for Disease Control – FY 22 Broad Agency Announcement
12.06.2021 |
arrow_forwardPotential target for treating and diagnosing Lyme disease discovered
11.30.2021 |
arrow_forwardA hope for Lyme disease? New vaccine targets ticks
11.17.2021 |
arrow_forwardLymeX Exemplifies the Power of Partnerships after One Year of Progress
10.20.2021 |
arrow_forwardA selective antibiotic for Lyme disease
10.14.2021 |
arrow_forwardLuminary Labs to Design LymeX Diagnostics Moonshot
09.17.2021 |
arrow_forwardThe Complex Legacies of Lyme Disease
08.19.2021 |
arrow_forwardRecent Progress in Lyme Disease and Remaining Challenges
08.18.2021 |
arrow_forwardLyme Disease Can Wreak Havoc on Mental Health
08.17.2021 |
arrow_forward{"post_type":"post","orderby":"date","order":"DESC","posts_per_page":"12","category__in":""}